Stock SRNE SORRENTO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Sorrento Therapeutics, Inc.

Equities

SRNE

US83587F2020

Delayed OTC Markets
Other stock markets
 17:26:20 30/04/2024 BST 		5-day change 1st Jan Change
0.016 USD +10.34% Intraday chart for Sorrento Therapeutics, Inc. -20.00% -87.04%
03-15 Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
03-12 News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dawson James Downgrades Sorrento Therapeutics to Neutral Rating From Buy
MT
Cantor Fitzgerald Initiates Sorrento Therapeutics at Overweight With $5 Price Target
MT
HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $20 From $26, Reiterates Buy Rating
MT
SORRENTO THERAPEUTICS : HC Wainwright Adjusts Sorrento Therapeutics' Price Target to $26 From $30, Keeps Buy Rating
MT
Sorrento Therapeutics, Inc. Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
CI
SORRENTO THERAPEUTICS : B. Riley Starts Sorrento Therapeutics at Buy With $26 Price Target
MT
SORRENTO THERAPEUTICS : Alliance Global Partners Starts Sorrento Therapeutics at Buy With $35 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRNE Stock
  4. News Sorrento Therapeutics, Inc.
  5. Analyst Reco.